Cargando…
The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
PURPOSE: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This research aimed to explore the real-world efficacy and safety o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356751/ https://www.ncbi.nlm.nih.gov/pubmed/35942069 http://dx.doi.org/10.2147/CMAR.S364125 |
_version_ | 1784763586474672128 |
---|---|
author | Zheng, Hao-Ran Jiang, Ai-Min Gao, Huan Liu, Na Zheng, Xiao-Qiang Fu, Xiao Zhang, Rui Ruan, Zhi-Ping Tian, Tao Liang, Xuan Yao, Yu |
author_facet | Zheng, Hao-Ran Jiang, Ai-Min Gao, Huan Liu, Na Zheng, Xiao-Qiang Fu, Xiao Zhang, Rui Ruan, Zhi-Ping Tian, Tao Liang, Xuan Yao, Yu |
author_sort | Zheng, Hao-Ran |
collection | PubMed |
description | PURPOSE: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This research aimed to explore the real-world efficacy and safety of anlotinib in ES-SCLC. METHODS: Pathologically confirmed ES-SCLC patients receiving anlotinib were enrolled for this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. RESULTS: In total, 202 patients were included in this study. The median PFS of all patients was 4.8 months [95% confidence interval (CI): 3.9–5.7], and the median OS was 7.6 months (95% CI 6.5–8.7). Respectively, the overall ORR and DCR were 30.2% and 87.1%. The univariate and multivariate Cox regression analyses revealed that patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1, plus chemotherapy or immunotherapy, plus radiotherapy, and post-medication hypertension might have longer PFS and OS. The PFS and OS were significantly prolonged in combination group than that in monotherapy group [PFS 6.0 vs 3.6 months, hazards ratio (HR)=0.49, 95% CI 0.34–0.70, P < 0.001; OS 9.2 vs 4.8 months, HR = 0.48, 95% CI 0.32–0.72, P < 0.001]. The main treatment-related adverse reactions were generally tolerated. The incidence of adverse reactions in combination group was higher than that in monotherapy group (75.0% vs 52.6%, P = 0.001). The most common adverse reaction was hypertension, followed by hand-foot syndrome and fatigue, regardless of monotherapy or combination group. CONCLUSION: Anlotinib is effective and well tolerated in patients with ES-SCLC in the real-world. The clinical efficacy of anlotinib combined with chemotherapy or immunotherapy is better than that of monotherapy. Further investigations are needed for prospective studies with larger sample size. |
format | Online Article Text |
id | pubmed-9356751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93567512022-08-07 The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study Zheng, Hao-Ran Jiang, Ai-Min Gao, Huan Liu, Na Zheng, Xiao-Qiang Fu, Xiao Zhang, Rui Ruan, Zhi-Ping Tian, Tao Liang, Xuan Yao, Yu Cancer Manag Res Original Research PURPOSE: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This research aimed to explore the real-world efficacy and safety of anlotinib in ES-SCLC. METHODS: Pathologically confirmed ES-SCLC patients receiving anlotinib were enrolled for this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. RESULTS: In total, 202 patients were included in this study. The median PFS of all patients was 4.8 months [95% confidence interval (CI): 3.9–5.7], and the median OS was 7.6 months (95% CI 6.5–8.7). Respectively, the overall ORR and DCR were 30.2% and 87.1%. The univariate and multivariate Cox regression analyses revealed that patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1, plus chemotherapy or immunotherapy, plus radiotherapy, and post-medication hypertension might have longer PFS and OS. The PFS and OS were significantly prolonged in combination group than that in monotherapy group [PFS 6.0 vs 3.6 months, hazards ratio (HR)=0.49, 95% CI 0.34–0.70, P < 0.001; OS 9.2 vs 4.8 months, HR = 0.48, 95% CI 0.32–0.72, P < 0.001]. The main treatment-related adverse reactions were generally tolerated. The incidence of adverse reactions in combination group was higher than that in monotherapy group (75.0% vs 52.6%, P = 0.001). The most common adverse reaction was hypertension, followed by hand-foot syndrome and fatigue, regardless of monotherapy or combination group. CONCLUSION: Anlotinib is effective and well tolerated in patients with ES-SCLC in the real-world. The clinical efficacy of anlotinib combined with chemotherapy or immunotherapy is better than that of monotherapy. Further investigations are needed for prospective studies with larger sample size. Dove 2022-08-02 /pmc/articles/PMC9356751/ /pubmed/35942069 http://dx.doi.org/10.2147/CMAR.S364125 Text en © 2022 Zheng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zheng, Hao-Ran Jiang, Ai-Min Gao, Huan Liu, Na Zheng, Xiao-Qiang Fu, Xiao Zhang, Rui Ruan, Zhi-Ping Tian, Tao Liang, Xuan Yao, Yu The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title | The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title_full | The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title_fullStr | The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title_full_unstemmed | The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title_short | The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study |
title_sort | efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356751/ https://www.ncbi.nlm.nih.gov/pubmed/35942069 http://dx.doi.org/10.2147/CMAR.S364125 |
work_keys_str_mv | AT zhenghaoran theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT jiangaimin theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT gaohuan theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT liuna theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT zhengxiaoqiang theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT fuxiao theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT zhangrui theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT ruanzhiping theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT tiantao theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT liangxuan theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT yaoyu theefficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT zhenghaoran efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT jiangaimin efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT gaohuan efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT liuna efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT zhengxiaoqiang efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT fuxiao efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT zhangrui efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT ruanzhiping efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT tiantao efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT liangxuan efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy AT yaoyu efficacyandsafetyofanlotinibinextensivestagesmallcelllungcanceramulticenterrealworldstudy |